Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207033099

Biotechnology & Medical Research

Market Closed - Nyse 16:10:00 2024-07-24 EDT 5-day change 1st Jan Change
1.672 USD -1.66% Intraday chart for Calidi Biotherapeutics, Inc. -6.08% -88.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2024. CI
Certain Common Stock of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2024. CI
Certain Stock Units of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2024. CI
Certain Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2024. CI
Calidi Biotherapeutics Secures New US Patent for SuperNova Technology Platform MT
Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board CI
Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin CI
Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split MT
Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $0.6 million in funding CI
Ladenburg Thalmann Initiates Calidi Biotherapeutics at Buy MT
Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care MT
Calidi Biotherapeutics Signs Virotherapy Deal With Siga Technologies -- Calidi Shares Surge Pre-Bell MT
Calidi Biotherapeutics Collaborates with Siga Technologies to Advance Calidi?S Revolutionary Rtnova Virotherapy for Lung Cancer and Metastatic Solid Tumors CI
Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting CI
Calidi Biotherapeutics, Inc. Announces Resignation of David Lapre as Director CI
Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Calidi Biotherapeutics Prices $6.1 Million Offering MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding CI
Sector Update: Health Care Stocks Firmer Late Afternoon MT
Calidi Biotherapeutics to Sell Common Stock MT
Chart Calidi Biotherapeutics, Inc.
More charts
Logo Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Employees
41
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.700USD
Average target price
15.00USD
Spread / Average Target
+782.35%
Consensus
  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. News Calidi Biotherapeutics, Inc.
  5. Sector Update: Health Care Stocks Advance Late Afternoon